Imagine a life where severe asthma sufferers could break free from the daily grind of oral corticosteroids (OCS). A groundbreaking study reveals that this might not be a distant dream anymore. Monthly injections of tezepelumab (Tezspire; AstraZeneca) have shown remarkable potential in reducing, or even eliminating, the need for these medications, according to research published in The Lancet Respiratory Medicine on November 26, 2025.
But here's where it gets even more exciting: The WAYFINDER study found that a staggering 50% of participants were able to completely stop taking OCS by the 52-week mark. This isn't just a minor improvement; it's a potential game-changer for those living with severe asthma. Researchers analyzed data from 298 participants who received tezepelumab 210mg subcutaneously every four weeks for up to a year. Among them, not only did half bid farewell to daily OCS, but a whopping 90% managed to reduce their daily dose to 5mg or less without compromising asthma control.
Tezepelumab, a monoclonal antibody, works by inhibiting thymic stromal lymphopoietin (TSLP), a cytokine that plays a key role in inflammatory responses. This mechanism is particularly crucial for severe asthma patients who often find standard treatments like high-dose inhaled corticosteroids (ICS) and long-acting β2-agonists insufficient. The National Institute for Health and Care Excellence (NICE) has already recommended tezepelumab for individuals aged 12 and older with severe asthma, provided they've had three or more exacerbations in the past year or are on maintenance OCS.
And this is the part most people miss: Despite the effectiveness of standard treatments, 3–10% of asthma patients still struggle with uncontrolled symptoms. Many of these individuals rely heavily on OCS, which, while effective, come with a laundry list of side effects, including osteoporosis, diabetes, ocular disorders, infections, renal impairment, and mental health issues like anxiety or depression. The WAYFINDER study highlights that tezepelumab could significantly reduce this burden, offering a safer, more sustainable treatment option.
Darush Attar-Zadeh, a clinical fellow respiratory pharmacist, emphasizes the transformative potential of this treatment: 'For patients dependent on daily OCS, the side effects are a constant concern. Studies like this give us hope that we can move beyond this reliance, especially as more evidence supports the steroid-sparing benefits of tezepelumab.' He advocates for a reevaluation of current access thresholds by NICE and commissioners, ensuring that more patients can benefit from this innovation.
In the UK, where approximately 7.2 million people live with asthma—4% of whom have severe asthma—this development is particularly significant. Samantha Walker, director of research and innovation at Asthma + Lung UK, hails this as 'an incredibly encouraging step forward that could revolutionize asthma care.' She underscores the urgent need for continued research funding, pointing out that lung health research remains underfunded despite lung conditions being the third leading cause of death in the UK.
Ellen Forty, research networks and partnership manager at Asthma + Lung UK, adds: 'This study provides a tested protocol for doctors to safely reduce oral steroids in severe asthma patients transitioning to tezepelumab. It’s a clear example of how biologics can shift the treatment paradigm away from long-term steroid use, which is fraught with risks.' She suggests that this approach could be extended to other biologics, further expanding treatment options for asthma patients.
But here’s the controversial question: As we celebrate the potential of tezepelumab, should we also be questioning why steroid-based treatments remain the default for severe asthma, given their well-documented side effects? Could this study mark the beginning of a broader shift toward biologic therapies in asthma management? We’d love to hear your thoughts in the comments below.
For more insights, explore how pharmacists are improving the management of uncontrolled asthma in adults in England: Improving the management of uncontrolled asthma for adults in England: where do pharmacists fit?
